GHK-Cu works through copper-dependent enzyme activity, extracellular matrix signaling, integrin pathways, MAPK/ERK cascades, and direct gene expression modulation
More may follow research from the Business Group on Health found 10% of companies that now cover GLP-1s for weight-loss plan to drop them by 2027
Arch Ophthalmol 116(7):874886
Hormonal treatment options include: Combined oral contraceptives : Continuous or cyclic regimens can reduce menstrual flow and suppress endometrial tissue activity Progestins : Available as oral medications, injections (depot medroxyprogesterone acetate), intrauterine devices (levonorgestrel-releasing IUD), or implants GnRH agonists : These medications induce a temporary menopausal state, effectively suppressing endometriosis but requiring add-back hormone therapy to minimize bone loss and vasomotor symptoms GnRH antagonists : FDA-approved oral options include elagolix (Orilissa) and relugolix/estradiol/norethindrone (Myfembree) with specific duration limits based on dosing and bone health considerations Aromatase inhibitors : Sometimes used in refractory cases, though not FDA-approved for this indication Bone mineral density monitoring is recommended for patients on long-term GnRH agonists or antagonists, particularly at higher doses or extended durations
It frames this as part of medication readiness rather than an optional extra
